Advertisement

Acta Neuropathologica

, Volume 107, Issue 5, pp 381–388 | Cite as

An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis

  • Ingmar Blümcke
  • Cordelia Luyken
  • Horst Urbach
  • Johannes Schramm
  • Otmar D. Wiestler
Regular Paper

Abstract

The semi-benign nature of diffuse astrocytomas is characterized by an increased risk for tumor recurrence and malignant transformation. In patients with intractable seizures, however, length of history and clinical follow-up studies indicate a better prognosis of this tumor entity. Here, we present a clinico-neuropathological study of 19 patients with chronic seizures and diffuse astrocytomas. In 6 patients, long-term survival and lack of tumor progression after a maximal follow-up time of 13 years appeared to correlate with a histologically isomorphic phenotype. Cytological hallmarks comprise low cellularity, lack of mitotic activity and highly differentiated astroglial elements infiltrating into adjacent brain parenchyma. Compared to “classical” variants of diffuse astrocytomas (WHO grade II), immunohistochemical reactions revealed a cellular proliferation below 1%, absence of nuclear p53 accumulation, and a lack of glial MAP2 and CD34 expression. Histopathologically, the isomorphic astrocytoma subtype can be distinguished from gangliogliomas, pilocytic astrocytomas and dysembryoplastic neuroepithelial tumors as well as from cortical dysplasia or reactive gliosis. Our data support the concept of a rare variant of diffuse astrocytomas occurring in young adults with long-term epilepsy and a favorable prognosis, which corresponds to WHO grade I.

Keywords

Brain Tumor Glioma Seizure 

Notes

Acknowledgements

We kindly thank C. Ullmann for her expert technical assistance. The study was supported by SFB TR3 (TP A1 and D1), Schr 285-1/2 and Bl 421/1-1 from the Deutsche Forschungsgemeinschaft.

References

  1. 1.
    Blümcke I, Wiestler OD (2002) Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 61:575–584Google Scholar
  2. 2.
    Blümcke I, Giencke K, Wardelmann E, Beyenburg S, Kral T, Sarioglu N, Pietsch T, Wolf HK, Schramm J, Elger CE, Wiestler OD (1999) The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol 97:481–490PubMedGoogle Scholar
  3. 3.
    Blümcke I, Becker AJ, Normann S, Hans V, Riederer BM, Krajewski S, Wiestler OD, Reifenberger G (2001) Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J Neuropathol Exp Neurol 60:984–993PubMedGoogle Scholar
  4. 4.
    Cosenza MA, Zhao ML, Shankar SL, Shafit-Zagardo B, Lee SC (2002) Up-regulation of MAP2e-expressing oligodendrocytes in the white matter of patients with HIV-1 encephalitis. Neuropathol Appl Neurobiol 28:480–488CrossRefPubMedGoogle Scholar
  5. 5.
    Daumas-Duport C, Scheithauer BW, Chodkiewicz JP, Laws ER, Vedrenne C (1988) Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery 23:545–556PubMedGoogle Scholar
  6. 6.
    Forsyth PA, Shaw EG, Scheithauer BW, O’Fallon JR, Layton DD Jr, Katzmann JA (1993) Supratentorial pilocytic astrocytomas. A clinicopathologic, prognostic, and flow cytometric study of 51 patients. Cancer 72:1335–1342PubMedGoogle Scholar
  7. 7.
    Fried I, Kim JH, Spencer DD (1994) Limbic and neocortical gliomas associated with intractable seizures: a distinct clinicopathological group. Neurosurgery 34:815–823PubMedGoogle Scholar
  8. 8.
    Goldring S, Rich KM, Picker S (1986) Experience with gliomas in patients presenting with a chronic seizure disorder. Clin Neurosurg 33:15–42PubMedGoogle Scholar
  9. 9.
    Haddad SF, Moore SA, Menezes AH, VanGilder JC (1992) Ganglioglioma: 13 years of experience. Neurosurgery 31:171–178PubMedGoogle Scholar
  10. 10.
    Kirkpatrick PJ, Honavar M, Janota I, Polkey CE (1993) Control of temporal lobe epilepsy following en bloc resection of low-grade tumors. J Neurosurg 78:19–25PubMedGoogle Scholar
  11. 11.
    Kleihues P, Cavenee WK (2000): Pathology and genetics of tumours of the nervous system World Health Organization Classification of Tumours. IARC, LyonGoogle Scholar
  12. 12.
    Kral T, Clusmann H, Urbach H, Schramm J, Elger CE, Kurthen M, Grunwald T (2002) Preoperative evaluation for epilepsy surgery (Bonn algorithm). Zentralbl Neurochir 63:101–105Google Scholar
  13. 13.
    Luyken C, Blümcke I, Fimmers R, Urbach H, Elger CE, Wiestler OD, Schramm J (2003) The spectrum of long-term epilepsy associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 44:822–830CrossRefPubMedGoogle Scholar
  14. 14.
    Morris HH, Matkovic Z, Estes ML, Prayson RA, Comair YG, Turnbull J, Najm I, Kotagal P, Wyllie E (1998) Ganglioglioma and intractable epilepsy: clinical and neurophysiologic features and predictors of outcome after surgery. Epilepsia 39:307–313PubMedGoogle Scholar
  15. 15.
    Nelson JS, Bruner JM, Wiestler OD, Vandenberg SR (2000) Ganglioglioma and gangliocytoma. In: Cavenee WK (ed) Pathology and genetics of tumours of the nervous system. World Health Organization Classification of Tumours. IARC, Lyon, pp. 96–98Google Scholar
  16. 16.
    Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP, Lacy J, Tsukerman L, Makuch R (1996) Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38:872–878PubMedGoogle Scholar
  17. 17.
    Shafit-Zagardo B, Davies P, Rockwood J, Kress Y, Lee SC (2000) Novel microtubule-associated protein-2 isoform is expressed early in human oligodendrocyte maturation. Glia 29:233–245CrossRefPubMedGoogle Scholar
  18. 18.
    Silver JM, Rawlings CE 3rd, Rossitch E Jr, Zeidman SM, Friedman AH (1991) Ganglioglioma: a clinical study with long-term follow-up. Surg Neurol 35:261–266PubMedGoogle Scholar
  19. 19.
    Suzuki SO, Kitai R, Llena J, Lee SC, Goldman JE, Shafit-Zagardo B (2002) MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration. J Neuropathol Exp Neurol 61:403–412PubMedGoogle Scholar
  20. 20.
    Zentner J, Wolf HK, Ostertun B, Hufnagel A, Campos MG, Solymosi L, Schramm J (1994) Gangliogliomas: clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 57:1497–1502PubMedGoogle Scholar
  21. 21.
    Zentner J, Hufnagel A, Wolf HK, Ostertun B, Behrens E, Campos MG, Elger CE, Wiestler OD, Schramm J (1997) Surgical treatment of neoplasms associated with medically intractable epilepsy. Neurosurgery 41:378–386PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Ingmar Blümcke
    • 1
  • Cordelia Luyken
    • 2
    • 6
  • Horst Urbach
    • 3
  • Johannes Schramm
    • 2
  • Otmar D. Wiestler
    • 4
    • 5
  1. 1.Department of NeuropathologyUniversity of Erlangen-NürnbergErlangenGermany
  2. 2.Department of NeurosurgeryUniversity of BonnBonnGermany
  3. 3.Department of NeuroradiologyUniversity of BonnBonnGermany
  4. 4.Department of NeuropathologyUniversity of BonnBonnGermany
  5. 5.German Cancer Research Center (DKFZ)HeidelbergGermany
  6. 6.Department of NeurosurgeryHeinrich Heine University of DüsseldorfDüsseldorfGermany

Personalised recommendations